Alston & Bird LLP
Alston & Bird LLP filed a Q2 report for Travere Therapeutics on July 20, 2026, reporting $70,000 in lobbying income.
Lobbying for Travere Therapeutics · Prescription pharmaceutical manufacturer of medications.
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.
H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.
Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs. Most-Favored Nation and International Reference Pricing proposals. PDUFA/regulatory review process.
The Newborn Screening Reauthorization Act, and improving funding of newborn screening implementation; Importance of patient voice in rare kidney disease.
H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit.